Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20477700 | 1.00 | CHRM1 (0.57) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL20477703 | 1.00 | CHRM1 (0.57) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL19331052 | 0.98 | CHRM1 (0.60) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL20477776 | 0.92 | KCNH2 (0.56) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL20477777 | 0.92 | KCNH2 (0.56) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL20477779 | 0.92 | KCNH2 (0.56) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL23827746 | 0.90 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL21654995 | 0.90 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL30211626 | 0.90 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL20477731 | 0.89 | CHRM1 (0.57) | CHRM1KCNH2ALOX5CYP2C9GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366679-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-10548899-B2 | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20180303841-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3366679-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180303841-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885KCNH2 351/4885ALOX5 1485/4885 |
| US-10548899-B2 | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885KCNH2 127/4885ALOX5 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.